[ENDP] Endo International plc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 16.27 Change: 0.5 (3.17%)
Ext. hours: 16.25 Change: -0.02 (-0.12%)

chart ENDP

Refresh chart

Strongest Trends Summary For ENDP

ENDP is in the medium-term down -35% below S&P in 4 months and down -60% below S&P in 1 year. In the long-term down -93% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women?s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men?s and women?s health, and prostate health. The company?s products also inc

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-1.55% Sales Growth - 4 Quarters -15.23% Sales Growth - Q/Q-10.73% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.55% ROE-8.7% ROI-3.62%
Current Ratio1.55 Quick Ratio1.37 Long Term Debt/Equity2.86 Debt Ratio0.83
Gross Margin49.62% Operating Margin-27.98% Net Profit Margin-11.54% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities996.86 M Cash From Operating Activities-930.48 M Gross Profit329.86 M
Net Profit-89.81 M Operating Profit45.75 M Total Assets14.15 B Total Current Assets5.33 B
Total Current Liabilities3.44 B Total Debt5.39 B Total Liabilities10.01 B Total Revenue714.13 M
Technical Data
High 52 week18.3 Low 52 week5.43 Last close7.8 Last change4.98%
RSI38.08 Average true range0.39 Beta0.73 Volume2.59 M
Simple moving average 20 days1.04% Simple moving average 50 days-9.26% Simple moving average 200 days-35.37%
Performance Data
Performance Week9.09% Performance Month-2.62% Performance Quart-18.41% Performance Half-52.35%
Performance Year39.04% Performance Year-to-date6.85% Volatility daily2.7% Volatility weekly6.03%
Volatility monthly12.36% Volatility yearly42.82% Relative Volume179.67% Average Volume3.15 M
New High New Low


2019-06-10 08:07:56 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-06-08 09:30:01 | Why Is Endo ENDP Down 38.9% Since Last Earnings Report?

2019-06-06 07:30:00 | Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get _In Touch_ With Their Anatomy This Men's Health Month

2019-05-23 12:07:29 | This May Hurt a Little Or a Lot as Opioids Haunt Pharma Bonds

2019-05-22 17:55:43 | Larry Robbins' Top 6 Buys of the 1st Quarter

2019-05-17 07:00:00 | Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019

2019-05-16 10:56:41 | Introducing Endo International NASDAQ:ENDP, The Stock That Tanked 91%

2019-05-16 09:01:36 | Endo International’s 2019 Key Growth Drivers

2019-05-15 17:00:00 | Endo to Participate at RBC Healthcare Conference

2019-05-14 16:00:08 | There's misinformation out there on generic drugs: Association of Accessible Medicines CEO

2019-05-13 11:42:00 | Why Endo International Shares Are Under Pressure Today

2019-05-10 14:41:06 | Endo ENDP Q1 Earnings & Revenues Beat Estimates

2019-05-10 14:24:18 | Endo International ENDP Q1 2019 Earnings Call Transcript

2019-05-09 18:04:07 | Edited Transcript of ENDP earnings conference call or presentation 9-May-19 11:30am GMT

2019-05-09 08:05:12 | Endo International ENDP Beats Q1 Earnings and Revenue Estimates

2019-05-09 07:46:08 | Endo: 1Q Earnings Snapshot

2019-05-09 07:06:56 | Drugmaker Endo posts narrower first-quarter loss

2019-05-09 06:58:36 | Drugmaker Endo quarterly results beat on robust sales of Xiaflex

2019-05-09 06:30:00 | Endo Reports First-Quarter 2019 Financial Results

2019-05-07 09:40:01 | BioDelivery BDSI Stock Up on Q1 Earnings and Sales Beat

2019-05-07 08:06:43 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?

2019-05-02 12:41:33 | Is Endo International plc ENDP A Good Stock To Buy ?

2019-05-02 10:32:02 | Analysts Estimate Endo International ENDP to Report a Decline in Earnings: What to Look Out for

2019-05-02 10:11:02 | What's in Store for BioDelivery BDSI This Earnings Season?

2019-05-01 17:35:00 | Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product

2019-04-30 08:02:12 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-04-10 17:00:00 | Endo to Announce First-Quarter 2019 Financial Results

2019-04-09 14:04:01 | When Will Endo International plc NASDAQ:ENDP Breakeven?

2019-04-09 10:51:12 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-04-05 07:30:00 | Endo Begins Shipment of Authorized Generic Version of PROVENTIL® albuterol sulfate HFA Inhalation Aerosol in the United States

2019-04-02 11:55:39 | See what the IHS Markit Score report has to say about Endo International PLC.

2019-04-01 12:38:52 | Drug companies that benefit from the war on opioid addiction

2019-04-01 11:16:28 | Drug companies that benefit from the war on opioid addiction

2019-03-30 09:30:01 | Why Is Endo ENDP Down 26.9% Since Last Earnings Report?

2019-03-27 21:11:00 | Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes

2019-03-25 16:24:10 | Endo International: Wall Street Ratings Not Very Favorable?

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-19 07:30:00 | Endo Announces Publication Of Collagenase Clostridium Histolyticum CCH Phase 2 Data In Dermatologic Surgery

2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up

2019-03-14 20:06:00 | Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations

2019-03-14 20:06:00 | Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

2019-03-14 12:01:16 | Endo Finance Co. -- Moody's downgrades Endo's secured debt to Ba3, unsecured notes to Caa1; B2 CFR affirmed

2019-03-14 11:01:03 | Insys Plunges on Auditor's Concern About Insufficient Funds

2019-03-14 07:54:00 | Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes

2019-03-14 07:51:00 | Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

2019-03-12 09:35:01 | Is Endo International ENDP a Great Stock for Value Investors?

2019-03-11 13:13:34 | Opioid litigation concerns weigh on pharmaceutical loan borrowers

2019-03-11 10:30:56 | What’s Expected to Drive Endo’s Growth in Fiscal 2019?

2019-03-11 09:00:57 | Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts